<VariationArchive VariationID="1453095" VariationName="NM_058216.3(RAD51C):c.502dup (p.Arg168fs)" VariationType="Duplication" Accession="VCV001453095" Version="7" RecordType="classified" NumberOfSubmissions="2" NumberOfSubmitters="2" DateLastUpdated="2024-02-28" DateCreated="2022-03-28" MostRecentSubmission="2024-02-20">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1432235" VariationID="1453095">
      <GeneList>
        <Gene Symbol="RAD51C" FullName="RAD51 paralog C" GeneID="5889" HGNC_ID="HGNC:9820" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>17q22</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="58692573" stop="58735611" display_start="58692573" display_stop="58735611" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="56769962" stop="56811691" display_start="56769962" display_stop="56811691" Strand="+" />
          </Location>
          <OMIM>602774</OMIM>
          <Haploinsufficiency last_evaluated="2020-07-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=RAD51C">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-07-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=RAD51C">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_058216.3(RAD51C):c.502dup (p.Arg168fs)</Name>
      <CanonicalSPDI>NC_000017.11:58696789:A:AA</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>17q22</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="58696789" stop="58696790" display_start="58696789" display_stop="58696790" variantLength="1" positionVCF="58696789" referenceAlleleVCF="T" alternateAlleleVCF="TA" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="56774150" stop="56774151" display_start="56774150" display_stop="56774151" variantLength="1" positionVCF="56774150" referenceAlleleVCF="T" alternateAlleleVCF="TA" />
      </Location>
      <ProteinChange>R168fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_314" sequenceAccession="LRG_314">
            <Expression>LRG_314:g.9189dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.10" sequenceAccession="NC_000017" sequenceVersion="10" change="g.56774151dup" Assembly="GRCh37">
            <Expression>NC_000017.10:g.56774151dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_058216.3" sequenceAccession="NM_058216" sequenceVersion="3" change="c.502dup" MANESelect="true">
            <Expression>NM_058216.3:c.502dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_478123.1" sequenceAccession="NP_478123" sequenceVersion="1" change="p.Arg168fs">
            <Expression>NP_478123.1:p.Arg168fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.11" sequenceAccession="NC_000017" sequenceVersion="11" change="g.58696790dup" Assembly="GRCh38">
            <Expression>NC_000017.11:g.58696790dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_023199.1" sequenceAccession="NG_023199" sequenceVersion="1" change="g.9189dup">
            <Expression>NG_023199.1:g.9189dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_047169.1" sequenceAccession="NG_047169" sequenceVersion="1" change="g.290dup">
            <Expression>NG_047169.1:g.290dup</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2143747561" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_058216.3(RAD51C):c.502dup (p.Arg168fs) AND Fanconi anemia complementation group O" Accession="RCV002000123" Version="5">
        <ClassifiedConditionList TraitSetID="1880">
          <ClassifiedCondition DB="MedGen" ID="C3150653">Fanconi anemia complementation group O</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-07-14" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
      <RCVAccession Title="NM_058216.3(RAD51C):c.502dup (p.Arg168fs) AND Breast-ovarian cancer, familial, susceptibility to, 3" Accession="RCV003336474" Version="2">
        <ClassifiedConditionList TraitSetID="1881">
          <ClassifiedCondition DB="MedGen" ID="C3150659">Breast-ovarian cancer, familial, susceptibility to, 3</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2023-05-31" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2023-07-14" NumberOfSubmissions="2" NumberOfSubmitters="2" DateCreated="2022-03-28" MostRecentSubmission="2024-02-20">
        <ReviewStatus>criteria provided, multiple submitters, no conflicts</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">20400964</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">21990120</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">24800917</ID>
        </Citation>
        <Citation Type="general">
          <ID Source="PubMed">29278735</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="1880" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6757" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Fanconi anemia complementation group O</ElementValue>
                <XRef ID="MONDO:0013248" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">FANCO</ElementValue>
                <XRef Type="MIM" ID="613390" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Fanconi anemia (FA) is characterized by physical abnormalities, bone marrow failure, and increased risk for malignancy. Physical abnormalities, present in approximately 75% of affected individuals, include one or more of the following: short stature, abnormal skin pigmentation, skeletal malformations of the upper and/or lower limbs, microcephaly, and ophthalmic and genitourinary tract anomalies. Progressive bone marrow failure with pancytopenia typically presents in the first decade, often initially with thrombocytopenia or leukopenia. The incidence of acute myeloid leukemia is 13% by age 50 years. Solid tumors – particularly of the head and neck, skin, and genitourinary tract – are more common in individuals with FA.</Attribute>
                <XRef ID="NBK1401" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15656" />
                <XRef ID="15656" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301575</ID>
                <ID Source="BookShelf">NBK1401</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="FARF, 2008">
                <URL>http://www.fanconi.org/images/uploads/other/Guidelines_for_Diagnosis_and_Management.pdf</URL>
                <CitationText>Fanconi Anemia Research Fund, Guidelines for Diagnosis and Management, 2008 (See 2020 Update)</CitationText>
              </Citation>
              <Citation Type="practice guideline" Abbrev="FARF, 2020">
                <URL>https://www.fanconi.org/images/uploads/other/Fanconi_Anemia_Clinical_Care_Guidelines_5thEdition_web.pdf</URL>
                <CitationText>Fanconi Anemia Clinical Care Guidelines, Fifth Edition.</CitationText>
              </Citation>
              <XRef ID="84" DB="Orphanet" />
              <XRef ID="C3150653" DB="MedGen" />
              <XRef ID="MONDO:0013248" DB="MONDO" />
              <XRef Type="MIM" ID="613390" DB="OMIM" />
            </Trait>
          </TraitSet>
          <TraitSet ID="1881" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="6648" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">RAD51C-Related Breast/Ovarian Cancer</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Breast-ovarian cancer, familial 3</ElementValue>
                <XRef ID="Breast-ovarian+cancer%2C+familial+3/7867" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Breast-ovarian cancer, familial, susceptibility to, 3</ElementValue>
                <XRef ID="MONDO:0013253" DB="MONDO" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">BROVCA3</ElementValue>
                <XRef Type="MIM" ID="613399" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="15657" />
                <XRef ID="15657" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Neoplasm</Attribute>
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="keyword">Hereditary cancer syndrome</Attribute>
              </AttributeSet>
              <XRef ID="145" DB="Orphanet" />
              <XRef ID="C3150659" DB="MedGen" />
              <XRef ID="MONDO:0013253" DB="MONDO" />
              <XRef Type="MIM" ID="613399" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="7567885" SubmissionDate="2023-10-23" DateLastUpdated="2023-10-28" DateCreated="2023-10-21">
        <ClinVarSubmissionID localKey="102497622|OMIM:613399" />
        <ClinVarAccession Accession="SCV004043908" DateUpdated="2023-10-28" DateCreated="2023-10-21" Type="SCV" Version="2" SubmitterName="Myriad Genetics, Inc." OrgID="507240" OrganizationCategory="laboratory" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-05-31">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This variant is considered pathogenic. This variant creates a frameshift predicted to result in premature protein truncation.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Myriad Autosomal Dominant, Autosomal Recessive and X-Linked Classification Criteria (2023)</Attribute>
          <Citation>
            <URL>https://submit.ncbi.nlm.nih.gov/ft/byid/8ufcwsf2/myriad_genetics_classification_criteria_2023.pdf</URL>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>unknown</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="RAD51C" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <Location>
            <SequenceLocation Assembly="hg19" Chr="17" alternateAllele="AA" referenceAllele="A" start="56774151" stop="56774151" />
          </Location>
          <OtherNameList>
            <Name Type="SubmitterVariantId">102497622</Name>
          </OtherNameList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="OMIM" ID="613399" Type="MIM" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB13911051</SubmissionName>
          <SubmissionName>SUB13922314</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
      <ClinicalAssertion ID="4246351" SubmissionDate="2024-02-08" DateLastUpdated="2024-02-20" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="9647705|MedGen:C3150653" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002229198" DateUpdated="2024-02-20" DateCreated="2022-03-28" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2023-07-14">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">20400964</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">21990120</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">24800917</ID>
          </Citation>
          <Citation>
            <ID Source="PubMed">29278735</ID>
          </Citation>
          <Comment>This variant has not been reported in the literature in individuals affected with RAD51C-related conditions. This sequence change creates a premature translational stop signal (p.Arg168Lysfs*35) in the RAD51C gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in RAD51C are known to be pathogenic (PMID: 20400964, 21990120, 24800917, 29278735). This variant is not present in population databases (gnomAD no frequency). ClinVar contains an entry for this variant (Variation ID: 1453095). For these reasons, this variant has been classified as Pathogenic.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="RAD51C" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.56774150_56774151insA</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C3150653" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14200314</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4246351" TraitType="Disease" MappingType="XRef" MappingValue="C3150653" MappingRef="MedGen">
        <MedGen CUI="C3150653" Name="Fanconi anemia complementation group O" />
      </TraitMapping>
      <TraitMapping ClinicalAssertionID="7567885" TraitType="Disease" MappingType="XRef" MappingValue="613399" MappingRef="OMIM">
        <MedGen CUI="C3150659" Name="Breast-ovarian cancer, familial, susceptibility to, 3" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

